Patent ID: 7601753

Claim:
A compound having the structure: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein R 1 is -L 1 -J; R 2 is —(C═O)—W; R 3 is -L 2 -Q; L 1 is a linker selected from the group consisting of —(CH 2 ) y —, —O—(CH 2 ) y —, —O—, —NH—(CH 2 ) y —, —(C═O)(CH 2 ) y —, —(C═O)—O—(CH 2 ) y —, —CH 2 (C═O)NH—, and —(C═O)—NH—(CH 2 ) y —; J is a ring structure selected from the group consisting of substituted or unsubstituted aromatic carbocyclic rings, substituted or unsubstituted non-aromatic carbocyclic rings, substituted or unsubstituted aromatic fused carbobicyclic ring groups, substituted or unsubstituted aromatic carbocyclic ring groups wherein the rings are joined by a bond or —O—, and substituted or unsubstituted aromatic fused heterobicyclic ring groups; wherein in each instance the rings comprise 5 or 6 ring atoms; W is a heteroatom unit selected from the group consisting of —NHCOCH 3 , —CONHCH 3 , —NH(C═NH)NHMe, —NH(C═NH)NHEt, —NH(C═NH)NHPr, —NH(C═NH)NHPr-I, —NH(C═NH)NH 2 , —NH(C═O)OCH 3 , —NH(C═O)CH 3 , NH(C═O)NH 2 , and —NH(C═O)NHCH 3 ; L 2 is a linker selected from the group consisting of Q is an aromatic carbocyclic ring selected from the group consisting of phenyl, substituted phenyl, naphthyl and substituted naphthyl; R 4 is —R 5 or —R 5 —R 6 ; R 5 is from one to three amino acid residues or an amine capping group, provided that if R 6 is present, R 5 is at least one amino acid residue; R 6 is H or an amine capping group; and y is at each occurrence independently from 0 to 6; wherein the carbon atoms marked with an asterisk can have any stereochemical configuration.